In Brief: Acutek v. CNS
This article was originally published in The Tan Sheet
Executive Summary
Acutek v. CNS: Acutek denies allegations that its Clear Passage reissue patent is invalid in its reply to CNS' counterclaim, filed Feb. 28 in the U.S. District Court Central District of California. CNS, which markets Breathe Right nasal strips, also had claimed that Acutek had made "false, misleading and deceptive" statements "likely to cause damage...to CNS" in press releases about the case and asked for damages ("The Tan Sheet" Feb. 24, p. 25). Acutek responds that the releases constitute commercial speech with First Amendment protection. Acutek filed the patent infringement suit on Jan. 6 ("The Tan Sheet" Jan. 31, p. 5)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning